Supplementary Information for:

Integrity of glycosylation processing of a glycan-depleted trimeric HIV-1 immunogen targeting key B-cell lineages

Anna-Janina Behrens[1], Abhinav Kumar[1], Max Medina-Ramirez[2], Albert Cupo[3], Kevin Marshall[3], Victor C. Portillo[3], David J. Harvey[1], Gabriel Ozorowski[5], Nicole Zitzmann[1], Ian A. Wilson[4,5], Andrew B. Ward[5], John P. Moore[3], Rogier W. Sanders[2,3], Max Crispin[1,6]*

[1]Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK

[2]Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, the Netherlands

[3]Department of Microbiology and Immunology, Weill Cornell Medical College, New York, New York, NY 10021, US

[4]Department of Integrative Structural and Computational Biology, IAVI Neutralizing Antibody Center and CAVD, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA 92037, USA

[5]Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

[6]Centre for Biological Sciences and Institute for Life Sciences, University of Southampton, Southampton SO17 1BJ, UK

*To whom correspondence should be addressed, Max Crispin, Email: max.crispin@soton.ac.uk, Tel: +44 (0)23 8059 4268.

Table of contents:



Figure S1. Glycan sequencing of BG505 SOSIP.v4.1-GT1 trimers by exoglycosidase digestion, related to Figure 2. Peaks were assigned by a sequential enzymatic digestion of 2-AA labelled glycans with a panel of exoglycosidases, followed by HILIC-UPLC analysis. The top panel shows the undigested glycan profile of BG505 SOSIP.v4.1-GT1 trimers produced in CHO cells. The profiles below represent digestions with the following exoglycosidases: Neuraminidase from *Clostridium perfringens*, β1,4-galactosidase from *Streptococcus pneumonia*, α-L-fucosidase from bovine kidney and β-*N*-acetylglucosaminidase from *S. pneumonia*. The HILIC-UPLC spectra of BG505 SOSIP.v4.1-GT1 looks highly similar to a previously published exoglycosidase array of BG505 SOSIP.664 produced in CHO cells (1).

Table S1. Overview of the thermostability of BG505 SOSIP trimers, related to Figure 1.

Construct	Cell line	Purification	T_m (°C)	Reference
SOSIP.664	HEK 293T, Transient	2G12+SEC	68.1	(2)
SOSIP.664	HEK 293T, stable	2G12+SEC	66.9	(3)
SOSIP.664	CHO, stable	2G12+SEC	66.3	(3)
SOSIP.v4.1	HEK 293F, transient	2G12+SEC	69.5	(4)
SOSIP.v4.1	CHO, stable	2G12+SEC	68.7	this paper
SOSIP.v4.1-GT1	HEK 293T, transient	PGT145+SEC	67.7	(5)
SOSIP.v4.1-GT1	CHO, stable	2G12+SEC	67.5	this paper

Table S2. Relative abundances of oligomannose-type glycan on BG505 SOSIP trimers, related to Figure 2. Abundances (as percentages of total glycans) of oligomannose-type glycans $Man_{5-9}GlcNAc_2$ (Man5-9), calculated after digestion of released glycans with Endoglycosidase H.

	Man5	Man6	Man7	Man8	Man9	Total
SOSIP.v4.1-GT1 gp140	8	6	8	17	18	57
SOSIP.664 gp140	5	7	8	15	23	59
SOSIP.v4.1-GT1 gp120	9	6	9	19	26	69
SOSIP.664 gp120	6	7	8	18	29	68
SOSIP.v4.1-GT1 gp41	2	1	1	0	0	4
SOSIP.664 gp41	1	6	4	1	10	12

Table S3. Library of glycan structures identified on BG505 SOSIP.v4.1-GT1 and SOSIP.664 trimers, related to Figure 3. The structures are represented as in the legend to Figure 3, using the Oxford glycan nomenclature (Oxford) as previously described (6). Da: Dalton; MW: Molecular weight; Calc: Calculated. Table S3 is available on-line as a separate file.

Table S4. N-linked glycopeptide compositions of trypsin- and chymotrypsin-digested BG505 SOSIP.v4.1-GT1 and SOSIP.664 trimers identified by LC-ESI MS, related to Figure 4. (A) SOSIP.v4.1-GT1 peak list; (B) SOSIP.664 peak list (in a separate Excel sheet). Site: N-glycosylation site; XIC: Extracted ion chromatogram; Exp.: Experimental determined mass (shown as a range when different charge states and/or different scans were recorded); Calc.: Calculated mass. All cysteines are carbamidomethylated. Lower case letters in the sequence indicate the positions of the modifications. Table A contains data from two analytical replicates per digest. Table S4 is available on-line as a separate file.

Supplementary References

1. **Pritchard LK, Vasiljevic S, Ozorowski G, Seabright GE, Cupo A, Ringe R, Kim HJ, Sanders RW, Doores KJ, Burton DR, Wilson IA, Ward AB, Moore JP, Crispin M.** 2015. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Reports **11:**1604-1613.

2. **Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.** 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathogens **9:**e1003618.

3. **Chung NPY, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson Ia, Ward AB, Marozsan AJ, Moore JP, Cupo A.** 2014. Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology **11:**33-33.

4. **de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.** 2015. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell **163:**1702-1715.

5. **Medina-Ramirez M, Garces F, Escolano A, Skog P, de Taeye SW, Moral-Sanchez I, Dosenovic P, Hua Y, McGuire AT, Gitlin Y, van der Woude P, Freund NT, Yasmeen A, Behrens A-J, Ozorowski G, Sliepen K, Blane T, Kootstra NA, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW.** 2017. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med **under revision**.

6. **Harvey DJ, Merry AH, Royle L, Campbell MP, Rudd PM.** 2011. Symbol nomenclature for representing glycan structures: Extension to cover different carbohydrate types. Proteomics **11:**4291-4295.